June 2, 2025
- Hansoh Pharma grants Regeneron Pharmaceuticals an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong, and Macau), to its investigational dual GLP-1/GIP receptor agonist.
- Hansoh Pharma receives an upfront payment of US$80 million and is eligible to receive development, regulatory, and sales milestone payments of up to US$1.93 billion, as well as double-digit royalties on potential future product sales.
Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK),has granted Regeneron Phammaceuticals, Inc.(Regeneron, NASDAQ: REGN) an exclusive worldwide license (excluding the Chinese Mainland, Hong Kong and Macau) to its
investigational dual GLP1/GIP receptor agonist HS-20094. HS-20094 has successfully completed multiple Phase II trials with positive efficacy and safety data and is currently being investigated in ongoing Phase III trial in China.
Under the agreement, Hansoh Pharma will receive an upfront payment of US$80 million and be eligible to receive up to US$1.93 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as double-digit royalties on potential future product sales.
The license agreement is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in the US, and any necessary regulatory filings.
Eliza Sun, Executive Director of Board, Hansoh Pharma, said: “We are excited to enter this license agreement with Regeneron Pharmaceuticals, a company with a renowned leadership team and a well-established track record in pushing the boundaries of innovative drug development. We look forward to HS-20094 potentially reaching patients worldwide through this new partnership.”
